International Psoriasis Council
Date: Wednesday 18 September 2019, 14.00-18.00
Room: F1 + F2
Program Title: The mechanistic model(s) of psoriasis: Autoimmune and/or autoinflammatory?
 |
Program Summary
This symposium will explore recent advances in the understanding of both the adaptive and innate immune pathways that lead to clinical phenotypes of psoriasis. Part 1 of this event will feature five faculty presentations with expert panel discussion on the immunological spectrum of psoriasis whereby the adaptive immune response drives chronic plaque psoriasis and innate and autoinflammatory responses contribute to rare subtypes of psoriasis. The complex interplay among autoreactive T-cells, lipid driven T cell response, cytokines, and genetic mutations will be highlighted.
Chairs
Michel Gilliet Lausanne, Switzerland) Johann Gudjonsson (Michigan, United States), Jörg Prinz (Munich, Germany)
Program
| 14.00-14.05 |
Welcome and Overview |
| PART I: LECTURES | |
| 14.05-14.30 | Autoreactive T cells in psoriasis Jörg Prinz (Munich) |
| 14.30-14.55 | Lipid driven T cell responses in psoriasis Chyung-Ru Wang (Chicago, USA) |
| 14.55-15.20 | The role of self in the innate immune system Michel Gilliet (Lausanne) |
| 15.20-15.35 | Break
|
| 15.35-16.00 | The role of interleukin-36 pathway deregulation in pustular psoriasis and psoriasis vulgaris: the autoinflammatory side of psoriasis Hervé Bachelez (Paris) |
| 16.00-16.25 | The impact of AP1S3 and CARD14 deregulation in psoriasis and psoriasis-like disorders Francesca Capon (London) |
| 16.25-16.55 | Panel Discussion Moderator: Johann Gudjonsson (Michigan, United States) |
| Part II: POSTERS
|
|
| 16.55-17.05 | Poster 388 Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/17 and neutrophilic pathways Christian Thoma (Biberach) |
| 17.05-17.15 | Poster 281 CARD14 variants are associated with palmar plantar pustulosis Athanasios Niaouris (London) |
| 17.15-17.25 | Poster 340 Circulating microRNAs in extracellular vesicles from plasma as potential biomarkers for psoriatic arthritis in patients with psoriasis Lorenzo Pasquali (Stockholm) |
| 17.25-17.35 | Poster 054 A Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Decreases the Transcriptional Signature of Th17 , Interleukin-12, and Interferon Pathways in Skin of Psoriasis: Results From a Phase 2 Trial Ian Catlett (Princeton, USA) |
| 17.35-17.45 | Poster 399 Distinct gene expression signatures differentiate clinical response to ustekinumab compared to adalimumab in psoriasis Ashley Rider (Newcastle Upon Tyne) |
| 17.45-17.55 | Poster 360 miR-378a is overexpressed in psoriasis keratinocytes and potentiates IL-17A-mediated inflammatory responses Enikö Pivarcsi Sonkoly (Stockholm) |
| 17.55-18.00 | Closing Comments Jörg Prinz (Munich) |